Pathogenetic processes

Pathogenetic processes (PPs) — are major molecular and phenotypic characteristics that determinate cancer as complex evolutionary disease process.


Name ( total associations | neutral | plus | minus )


Invasion ( 3205 / 1628 /
512
/
1065
)
migration ( 2587 / 1309 /
414
/
864
)
colony formation ( 439 / 225 /
55
/
159
)
cell cycle ( 254 / 133 /
45
/
76
)
Proliferation ( 3616 / 1828 /
578
/
1210
)
cell cycle progression ( 177 / 90 /
43
/
44
)
Cell growth ( 732 / 370 /
107
/
255
)
Senescence ( 65 / 36 /
21
/
8
)
cell cycle arrest ( 501 / 254 /
219
/
28
)
MTX resistance ( 3 / 2 /
0
/
1
)
Tomudex (TDX) resistance ( 1 / 1 /
0
/
0
)
Metastasis ( 1021 / 519 /
197
/
305
)
AKT signaling ( 251 / 127 /
42
/
82
)
cisplatin resistance ( 284 / 143 /
44
/
97
)
Autophagy ( 319 / 160 /
73
/
86
)
survival ( 134 / 69 /
23
/
42
)
Apoptosis ( 1620 / 824 /
524
/
272
)
cell viability ( 268 / 138 /
35
/
95
)
5fluorouracil resistance ( 98 / 58 /
16
/
24
)
G1-S checkpoint ( 7 / 4 /
2
/
1
)
Lung metastasis ( 55 / 29 /
11
/
15
)
DNA repair ( 55 / 28 /
19
/
8
)
TGF-beta signaling ( 368 / 207 /
79
/
82
)
motility ( 185 / 95 /
30
/
60
)
EMT ( 777 / 395 /
164
/
218
)
stemness ( 207 / 104 /
46
/
57
)
BMP signaling ( 108 / 63 /
13
/
32
)
Hedgehog (Hh) signaling ( 31 / 16 /
5
/
10
)
JAK/STAT signaling ( 96 / 49 /
25
/
22
)
Angiogenesis ( 272 / 141 /
44
/
87
)
growth ( 222 / 131 /
26
/
65
)
tumor-initiating properties ( 9 / 6 /
0
/
3
)
tumor growth ( 690 / 348 /
115
/
227
)
Chemoresistance ( 264 / 133 /
46
/
85
)
Paclitaxel resistance ( 61 / 31 /
12
/
18
)
beta-catenin signaling ( 51 / 26 /
11
/
14
)
Brain metastasis ( 2 / 1 /
0
/
1
)
docetaxel resistance ( 31 / 17 /
10
/
4
)
cyclophosphamide sensitivity ( 1 / 1 /
0
/
0
)
recurrence ( 2 / 2 /
0
/
0
)
adhesion ( 49 / 27 /
7
/
15
)
NF-kB signaling ( 143 / 73 /
39
/
31
)
Antiapoptosis ( 37 / 20 /
12
/
5
)
Oxaliplatin resistance ( 23 / 12 /
5
/
6
)
Anoikis ( 22 / 12 /
4
/
6
)
MET ( 18 / 10 /
8
/
0
)
differentiation ( 95 / 48 /
31
/
16
)
Tamoxifen resistance ( 19 / 10 /
6
/
3
)
Radioresistance ( 113 / 58 /
22
/
33
)
inflammation ( 73 / 37 /
13
/
23
)
redox homeostasis ( 3 / 3 /
0
/
0
)
Sorafenib resistance ( 28 / 14 /
6
/
8
)
tumor progression ( 82 / 42 /
24
/
16
)
aerobic glycolysis ( 61 / 31 /
10
/
20
)
ER stress ( 28 / 15 /
0
/
13
)
Oxaliplatin ( 2 / 1 /
1
/
0
)
cellular repair of DNA double-strand breaks ( 1 / 1 /
0
/
0
)
etoposide ( 7 / 4 /
2
/
1
)
RAS signaling pathway ( 8 / 5 /
1
/
2
)
doxorubicin resistance ( 65 / 33 /
8
/
24
)
multidrug resistance ( 20 / 11 /
4
/
5
)
ERK pathway (MAPK pathway) ( 139 / 70 /
22
/
47
)
Liver metastasis ( 26 / 15 /
4
/
7
)
scattering ( 1 / 1 /
0
/
0
)
HCPT (Hydroxycamptothecin) resistantance ( 1 / 1 /
0
/
0
)
cell polarity ( 1 / 1 /
0
/
0
)
cell spreading ( 8 / 6 /
0
/
2
)
Temozolomide (TMZ) resistance ( 26 / 13 /
5
/
8
)
WNT signaling ( 218 / 110 /
52
/
56
)
cancer progression ( 16 / 9 /
5
/
2
)
PI3K signaling ( 87 / 44 /
13
/
30
)
inflammatory monocyte recruitment ( 4 / 3 /
0
/
1
)
erythropoiesis ( 3 / 3 /
0
/
0
)
NK cell cytotoxicity ( 6 / 4 /
0
/
2
)
Response to genotoxic stress ( 2 / 2 /
0
/
0
)
mitoxantrone (MX) Resistance ( 1 / 1 /
0
/
0
)
Castrate Resistance ( 25 / 15 /
8
/
2
)
Bone metastasis ( 20 / 12 /
1
/
7
)
anchorage-independent growth ( 31 / 16 /
9
/
6
)
Camptothecin resistance ( 3 / 2 /
0
/
1
)
macrophage attraction ( 1 / 1 /
0
/
0
)
tumor-stroma interactions ( 3 / 2 /
1
/
0
)
Imatinib resistance ( 12 / 8 /
0
/
4
)
myeloid differentiation ( 27 / 14 /
7
/
6
)
microtubule-targeting drugs ( 4 / 4 /
0
/
0
)
disease-free survival ( 3 / 2 /
0
/
1
)
epirubicin resistance ( 5 / 3 /
2
/
0
)
Transformation ( 15 / 12 /
2
/
1
)
neutrophil chemotaxis ( 2 / 2 /
0
/
0
)
NOTCH signaling ( 55 / 28 /
15
/
12
)
gefitinib resistance ( 28 / 15 /
4
/
9
)
Hepatocyte differentation ( 2 / 2 /
0
/
0
)
poor prognosis ( 46 / 26 /
17
/
3
)
unfolded protein response ( 5 / 4 /
0
/
1
)
P38 signaling ( 29 / 15 /
10
/
4
)
Vorinostat Resistance ( 6 / 4 /
2
/
0
)
Osteolysis ( 5 / 3 /
0
/
2
)
EGFR-TKI resistance ( 2 / 2 /
0
/
0
)
Tumorigenesis ( 43 / 22 /
7
/
14
)
Adriamycin (Adr) resistance ( 26 / 14 /
3
/
9
)
lipogenesis ( 23 / 12 /
0
/
11
)
mTOR signaling ( 76 / 38 /
8
/
30
)
cytotoxicity ( 2 / 1 /
1
/
0
)
gluconeogenesis ( 4 / 2 /
0
/
2
)
chondrogenesis ( 1 / 1 /
0
/
0
)
Lapatinib resistance ( 2 / 1 /
0
/
1
)
Neratinib resistance ( 2 / 1 /
0
/
1
)
Afatinib resistance ( 2 / 1 /
0
/
1
)
daunorubicin (DNR) Resistance ( 4 / 2 /
2
/
0
)
Response to oxidative stress ( 5 / 5 /
0
/
0
)
T cell activation ( 3 / 2 /
1
/
0
)
gemcitabine resistance ( 42 / 21 /
7
/
14
)
genomic instability ( 4 / 2 /
1
/
1
)
glycolysis ( 11 / 11 /
0
/
0
)
insulin signaling ( 1 / 1 /
0
/
0
)
endothelial-mesenchymal transition ( 1 / 1 /
0
/
0
)
branching-morphogenesis ( 1 / 1 /
0
/
0
)
Taxanes (paclitaxel and docetaxel) resistance ( 8 / 7 /
0
/
1
)
Vinblastine (Velban) resistance ( 1 / 1 /
0
/
0
)
Hippo signaling pathway ( 164 / 82 /
65
/
17
)
glucose metabolism ( 18 / 9 /
3
/
6
)
BRCAness ( 2 / 1 /
1
/
0
)
BRAFi resistance ( 4 / 2 /
1
/
1
)
MEKi resistance ( 4 / 2 /
1
/
1
)
immunoevasion ( 18 / 9 /
4
/
5
)
MAPK/JNK Signaling Pathway ( 10 / 5 /
5
/
0
)
Hypoxic response ( 8 / 5 /
3
/
0
)
carboplatin resistance ( 2 / 1 /
0
/
1
)
Trastuzumab resistance ( 8 / 4 /
2
/
2
)
fibrosis ( 28 / 14 /
6
/
8
)
TRAIL resistance ( 2 / 1 /
0
/
1
)
Rapamycin resistance ( 2 / 1 /
0
/
1
)
Cetuximab resistance ( 20 / 10 /
7
/
3
)
BCL2 inhibitors resistance ( 2 / 1 /
0
/
1
)
Necrosis ( 4 / 2 /
1
/
1
)
pyroptosis ( 2 / 1 /
1
/
0
)